Search

The article presents the issue of EPM Weekly COVID-19 announcements. Topics include managing SARS-CoV-2 transmission associated with higher education; a report on the preliminary results of the COVID-19 testing and antibody prevalence surveillance in schools programme; and containing advice on the collection, transfer, and isolation of students.

This article presents news briefs related to the treatment of multiple sclerosis. One of the snippets report that Biogen Idec Inc. has identified a molecule in the central nervous system that may play a pivotal role in nerve repair and regeneration which could be used in the treatment of multiple sclerosis. Another snippet presents information on Chromos Molecular Systems Inc. that has entered into a letter of intent to acquire Targeted Molecules Corp., a privately held San Diego, California based biotechnology company focused on the research and development of two antibody product candidates in multiple sclerosis and acute thrombosis.

The article offers news briefs related to pharmaceutical industry. It was found that the gene APOE4 heightens the risk of developing Alzheimer disease later in life. Immuno-Biological Laboratories Co. Ltd. has sold the rights to its Alzheimer's antibodies. GlaxoSmithKline and Biovail Corp. have been given the signal to sell a generic version of Wellbutrin XL for major depressive disorder, by the Food and Drug Administration.